If Butterfly Network was on your watchlist instead of in your portfolio, the return may sting. Investors who held Butterfly Network from the start of the year are up 53.3%, including dividends. That move arrived alongside FDA clearance headlines and fresh licensing deals, yet those came after the decision date. The real puzzle is earlier. Should the bullish assumption that AI-driven software and HomeCare could shift revenue toward higher-margin recurring streams have been enough to spot this potential before results landed?
Butterfly Network is not the only name tied to this theme. Zero in on 37 healthcare AI stocks and compare how each one is priced.
Butterfly Network shares cost US$3.8 at the start of the period, and investors were essentially choosing between an AI optimism story and a more cautious reading of the same ultrasound opportunity.
The bullish narrative saw a Fair Value of US$4, a price implied by faith in its assumptions, relying on AI imaging and HomeCare shifting revenue into higher margin, recurring software, with revenue rising 19.2% a year and profit margin moving from a loss toward 12.3% by 2028.
The more conservative view pointed to a Fair Value of US$3.19, built on slower 15.8% annual revenue growth assumptions and concerns that sluggish domestic demand, volatile international funding, and heavy R&D spending could keep Butterfly Network loss making for longer.
The clearest fact is that Butterfly Network moved from US$21.49m in Q3 2025 revenue to US$32.60m in Q3 2026, while the net loss narrowed from US$33.97m to US$12.81m and net margin improved from a 158.1% loss to a 39.3% loss. That shift supported the optimistic case for better economics from AI software and Embedded deals, yet profitability remained unproven, so the evidence cut both ways.
The lesson is practical. When a story leans on higher margin recurring sales, track gross margin, segment mix and whether losses are shrinking. Then test whether that trend actually closes the gap to break-even rather than just lifting revenue.
Butterfly Network now trades at US$5.75, and this Narrative's Fair Value view sits below that level, so the author sees the market price as ahead of their own valuation work.
According to Gil263, an investor in the Simply Wall St Community, the core thesis leans on ultrasound-on-chip, Compass AI and the belief that cash reserves avoid heavy dilution. The key question is whether a buyer today can reasonably assume future funding needs are met without large new share issuance.
"On November 17, 2025, Butterfly Network’s subsidiary signed a five-year co-development and licensing agreement with Midjourney for exclusive access to its semiconductor-based ultrasound technology, securing a US$15 million upfront payment, US$10 million annual license fees, and further milestone and revenue-sharing potential. Midjourney’s partnership reflects growing industry interest in Butterfly’s ultrasound-on-chip innovation, coinciding with the company's launch of Compass AI, its latest AI-powered enterprise software platform aimed at improving healthcare workflow, compliance, and revenue capture."
That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for
Butterfly Network lives on medical images. All that scanning still needs somewhere to compute.
Hospitals and software vendors training AI tools rely on heavy duty processing power. Those AI factories keep growing more complex as workloads expand.
One specialist builds the chips, systems and software platforms that crunch these models at scale. Its focus is squeezing more AI work out of every unit of power.
If medical imaging AI takes off as hoped, demand for that capacity matters. Your question becomes how far this shared need for compute might reach.
One Narrative has put that dependency into a written case. → See the AI infrastructure company one Narrative values 106% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com